Dr. Thomas Prevot is a staff scientist in the Neurobiology of Depression and Aging Program at the Centre for Addiction and Mental Health (CAMH). He is also an assistant professor in the Departments of Psychiatry, Pharmacology and Toxicology at the University of Toronto.
Dr. Prevot received his PhD in Behavioral Neuropsychopharmacology from the University of Bordeaux in France in 2015 and started a postdoctoral fellowship in CAMH in 2016. He transitioned to a project scientist position in 2019, and then a staff scientist position in 2023. He is also an alumni of the EUREKA Institute for Translational Medicine, and the Canadian Representative for Biomedical Research Awareness Day (BRAD).
Areas of Research
Dr. Prevot’s research focuses on the neurobiology of stress, aging and their interactions, and on understanding how stress and aging affect quality of life and lead to psychiatric and neurodegenerative diseases. He has a keen interest at studying memory and cognitive dysfunctions across disorders using preclinical approaches. As the lead of a drug development program working with Dr. Etienne Sibille, he worked towards the discovery of novel molecules with the potential of reducing cognitive symptoms. This discovery enabled the creation of DAMONA Pharmaceuticals, an early-stage biotech co-founded by Dr. Sibille and CAMH.
As an ethologist and a behavioural pharmacologist, he has developed a unique expertise in the field of translational research, including the characterization of novel targets for therapeutic avenues and medication development for future clinical testing. Dr. Prevot is actively involved in the translational research and medicine landscape at the University of Toronto, working across disciplines and being an advocate for bench-to-bedside discovery, and biomedical research.
Publications
Dr. Thomas Prevot’s publications are available on Google Scholar.
More news is also available on his lab's website NDASibille/Prevot and on Twitter @PrevotLab.